Evommune Still Has Shot At Atopic Dermatitis With EVO756 After Urticaria Failure
The results of a Phase IIb trial in chronic spontaneous urticaria mean MRGPRX2 inhibition is unlikely to prove effective in that disease, but an analyst noted AD and migraine have biologically distinct mechanisms.
Scrip - June 29, 2026

Zymeworks Buys Theravance To Execute On New Business Strategy
The company will buy Theravance for $929m, gaining a revenue stream from a US profit-share with Viatris for the nebulized LAMA Yupelri for COPD.
Scrip - June 29, 2026

Fragrance Allergen Labeling In Spotlight With EU Deadline Imminent, California Not Far Behind
Expanded mandates for labeling fragrance allergens go into effect July 31 for products on the market in Europe.
HBW Insight - June 29, 2026

AstraZeneca Details Bone Health Data For Strensiq Successor
The company believes that efzimfotase alfa, its new treatment for hypophosphatasia, could become a $5bn blockbuster.
Scrip - June 29, 2026

Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - June 29, 2026

Execs On The Move: June 15–19, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - June 29, 2026

Ipsen Buys Kartos And Its Phase III Navtemadlin, Undeterred By MDM2 Setbacks
Ipsen is betting up to $1.75bn on Kartos Therapeutics and its MDM2 inhibitor navtemadlin, a Phase III add-on therapy for myelofibrosis patients.
Scrip - June 29, 2026

Over The Counter: The Economic and Social Value Of Probiotics, With IPA Europe’s Rosanna Pecere
HBW Insight speaks to IPA Europe's executive director Rosanna Pecere on the association's new socioeconomic assessment, which puts the potential savings from probiotics at around €10bn and argues the EU's inconsistent regulatory treatment of the term "probiotic" is holding much of that back.
HBW Insight - June 29, 2026

Sandoz Starts Generic Tirzepatide Race With FDA Filing Acceptance
Developed in-house by combining expertise in small molecules, devices, and biosimilars, Sandoz intends for its tirzepatide to be the first generic rival to Mounjaro/Zepbound autoinjectors.
Generics Bulletin - June 29, 2026

India Proposes Faster Medical Device Manufacturing License Timelines
India's health ministry has proposed cutting manufacturing license timelines for medical devices across risk classes, targeting greater regulatory efficiency — but industry body AiMeD has flagged a puzzling anomaly.
Medtech Insight - June 29, 2026

Roche Bets Flexible Economics Can Loosen The Batching Trap That Defines NGS
Roche pitches AXELIOS 1's reusable-sensor economics as the cure for the NGS "batching penalty," backed by early collaborator data and a near-term NICU use case, as it starts on the path from research-use to clinical diagnostics.
Medtech Insight - June 29, 2026

Pipeline Watch: Japan Dominates Thirty-Four Approvals Plus Seven Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - June 29, 2026

Biocon Grows Malaysian Insulin Presence With A $54m Government Tender Deal
Three multi-year insulin product agreements with Biocon will push Malaysia’s ambition for healthcare self-reliance and domestic manufacturing security.
Generics Bulletin - June 29, 2026

Top Medtechs’ Annual Average Growth Hits 8.5%
A handful of ranking changes among medtech’s topmost global tier in an industry showing healthy growth were reflected in In Vivo’s US dollar-rankings for calendar 2025.
In Vivo - June 29, 2026

CHMP Nods Deepen Crowded Denosumab, Pegfilgrastim Biosimilar Fields
The EMA’s CHMP has backed Ascend’s self-titled denosumab and Qilu’s Nylaspeg, adding further competition to already crowded European denosumab and pegfilgrastim biosimilar markets.
Generics Bulletin - June 29, 2026

Norwich Ruling Strengthens Bausch’s Grip On Xifaxan
Norwich Pharmaceuticals has lost its administrative-law challenge to the FDA over its skinny-label generic of Bausch Health’s Xifaxan, with the D.C. Circuit affirming that the agency was right to withhold final approval until Salix’s hepatic-encephalopathy patents expire in 2029.
Generics Bulletin - June 29, 2026

Getting The EU MDR ‘Mostly Right’ Is A Juggling Act – The German Industry View
Germany’s BVMed industry association head of regulation Christina Ziegenberg laid out the possible route ahead for the EU co-legislators’ negotiations over amendments to the MDR and IVDR.
Medtech Insight - June 29, 2026

‘Stop Talking And Do’: The Team Player Taking A Proactive Oversight Approach At Link Biologics
Reuben Dawkins, CEO and co-founder of Link Biologics, knows the catalysts for innovation. The In Vivo Rising Leader discusses the gap between scientific discovery and commercialization, highlighting the potential of TSG-6, a naturally occurring protein just waiting to be commercialized.
In Vivo - June 29, 2026

Roche Launches AXELIOS 1 Sequencer At $750,000, Targeting Illumina’s Market
Roche launches AXELIOS 1, a $750,000 sequencer offering $150 genomes and a sub-four-hour whole-genome turnaround under optimized conditions. With middle-ground read lengths and reusable sensor economics, will this broaden access or just add to an already crowded market.
Medtech Insight - June 29, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: China deal controls a hot BIO topic; pharma eyes $2 trillion in sales; Apogee helps AbbVie achieve vision; Sangamo files for bankruptcy; and a review of Weber’s time at Takeda.
Scrip - June 29, 2026